PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
about
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumabPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cellsBisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancerIL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumoursExosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages.Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.New insights into the role of EMT in tumor immune escape.High expression of B7-H6 in human glioma tissues promotes tumor progressionReprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers.PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.Checkpoint Blockade in Lung Cancer and Mesothelioma.Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian CancerSOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of OriginRecurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma.A New VISTA on combination therapy for negative checkpoint regulator blockade.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.Macrophages Polarized by Expression of ToxoGRA15II Inhibit Growth of Hepatic Carcinoma.An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.cGAS is essential for the antitumor effect of immune checkpoint blockade.Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.Emerging roles of p53 and other tumour-suppressor genes in immune regulationSquamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.
P2860
Q26740520-AFCC410B-9045-431D-8254-047D9E9AB45CQ28076473-25FF77D7-FFAD-4319-9A38-4BD76F3347C0Q30274619-3B66ECC7-6FE5-40C2-8E4E-D26FFB20862BQ30275174-A4C69062-0315-400F-9C6A-868357FE969DQ33651093-C8CBA095-A581-4095-9B51-0D6D469B1F70Q33684256-AE3E8BAA-63E6-42E4-A117-0213A653BFB2Q33702231-6B4B6772-6BB1-4F59-B0A1-6BA3EA209088Q33739857-C9CA2B29-274D-435A-8C42-AA6153EDED67Q33786422-BC121735-82DE-494E-A31F-3A806D28D249Q33837257-E2EAE75F-62EB-4790-AAF6-2B86301115B2Q33861833-1B9C4BAE-CDBB-405D-9DC7-4173785CD9CDQ33869781-3095A7E3-FDD8-4531-AD6A-1FD1860303DDQ33913978-B837FF99-B058-443B-9C4F-DAED6194024CQ33917658-193B8DCA-33D8-4DEC-9CD8-43098C45410EQ34047394-61A99177-EEBD-47D0-8A71-29D6C8C06246Q34538075-D9DDC30A-FBD8-4A94-923E-7877A707D916Q34550012-040C0E43-03DB-4873-9426-F86F64D10347Q36205148-138A784F-AC86-4F77-B717-64D8A8DF8DB9Q36295004-7B9C9574-AF87-48C9-B68E-BEC32A519386Q36353438-6E2FB794-8552-4048-A659-1E8BA73C2FEFQ36382143-BF81911D-7FCB-473F-B691-4CFECEA52619Q36868333-0E36A587-32B0-482A-ABB7-754C8150BF6DQ36922131-F562B02F-031F-4D74-A39E-9E40B87395CAQ37340964-05300B8E-820E-40B2-9485-79BEEAA5D855Q37414589-310028CD-9BDE-4521-B298-6D0585F6DF0FQ37427668-9234A037-937F-48C0-9F60-FC56A4DC3FCCQ37517581-28FBA313-D735-4FB0-A845-0BB6FAF10164Q37554718-EDBFB9FC-10FB-4158-AA51-29F634A5317EQ37566921-336BC0CC-DFB2-4D2A-8C94-837E609C3F9EQ37616487-94D2FAC5-0C69-496A-B880-A6F8A04A7386Q37626226-136F1A98-673A-4C95-BFF5-8774817C37AEQ37637462-E5444026-5A49-4519-84CC-37CB36DC3E93Q37637845-AEC19CCB-4891-4916-BD86-899CCCC86C87Q37644337-884A1905-E90E-4765-BFF5-6CA29064962DQ37658955-28C8C8F0-89BD-412B-A292-DFE506C73E3DQ37665652-B5838394-9958-4949-9CC3-BFB16030C24AQ37666015-6E6C35B3-3CD6-41CE-A1CA-B4761A859F2EQ37684668-AEDC0A82-6D98-4D5C-AE80-3264B6C783A9Q37686620-E3327755-AC4A-4A65-81E0-24A9561F7C03Q37705031-80B31242-232D-4B51-89C5-ADF47BDAD0DD
P2860
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@ast
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@en
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@nl
type
label
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@ast
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@en
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@nl
prefLabel
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@ast
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@en
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@nl
P2093
P2860
P3181
P1476
PD-L1 (B7-H1) and PD-1 pathway ...... e biomarkers, and combinations
@en
P2093
P2860
P304
P3181
P356
10.1126/SCITRANSLMED.AAD7118
P407
P577
2016-03-02T00:00:00Z